Agenus (AGEN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
13 May, 2026Voting matters and shareholder proposals
Proposal 4 seeks approval for a one-time exchange of underwater stock options held by employees, consultants, and non-employee directors for new options, with executive and director options priced at a 50% premium to fair market value on the exchange date.
The exchange is structured as a one-for-one share replacement, with no increase in the aggregate number of outstanding options.
Approval requires a majority of votes cast by stockholders present in person or by proxy; abstentions and broker non-votes will not affect the outcome.
The Board recommends a vote in favor of Proposal 4.
Executive compensation and say-on-pay
Executives and non-employee directors will receive replacement options with a strike price at 150% of the exchange date’s fair market value, aligning their compensation with future stock price appreciation.
Other employees and consultants will receive options at fair market value, restoring retention and motivation value.
Executives have elected to receive both base and annual bonus compensation entirely in stock and options, with no cash component.
The compensation committee selected this structure to avoid incremental cash outlay and to ensure executives benefit only after significant stock price appreciation.
Board of directors and corporate governance
The compensation committee evaluated alternatives and determined the one-for-one exchange with a premium strike for executives best aligns with stockholder interests.
Executive officers and non-employee directors are eligible to participate if they hold eligible options and remain in service through the exchange date.
Latest events from Agenus
- Q1 2026 delivered profitability, global asset expansion, and key regulatory and financial gains.AGEN
Q1 202611 May 2026 - Proxy seeks approval for director elections, equity plan increases, and a one-time option exchange.AGEN
Proxy filing1 May 2026 - Proxy seeks approval for director elections, equity plan amendments, and a one-time option exchange.AGEN
Proxy filing20 Apr 2026 - Strong clinical and commercial momentum positions the company for pivotal regulatory filings in 2026.AGEN
AGM 202631 Mar 2026 - BOT + BAL enters Phase 3 with $4.2M early access revenue and $91M Zydus capital boost.AGEN
Q4 202516 Mar 2026 - Zydus partnership secures manufacturing and capital, driving global access and pivotal trials for BOT/BAL.AGEN
Status update3 Feb 2026 - BOT/BAL data strong, cash up, but partnership losses and going concern risks persist.AGEN
Q2 20242 Feb 2026 - BOT/BAL shows robust efficacy in colorectal cancer, with pivotal trials and regulatory milestones ahead.AGEN
Wells Fargo 2024 Healthcare Conference22 Jan 2026 - BOT/BAL shows strong efficacy in hard-to-treat cancers, with pivotal data and regulatory steps ahead.AGEN
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026